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MCPIP1 Regulates Fibroblast Migration in 3-D
Collagen Matrices Downstream of MAP Kinases and
NF-κB
Jie Chao1,2, Xiaoniu Dai2, Tiffany Peña1, David A. Doyle1, Timothy M. Guenther1 and Mark A. Carlson1,3,4
The ﬁbroblast-populated three-dimensional (3-D) collagen matrix has been used to model matrix contraction,
cell motility, and general ﬁbroblast biology. MCPIP1 (monocyte chemotactic protein–induced protein 1) has been
shown to regulate inﬂammation, angiogenesis, and cellular motility. In the present study, we demonstrated
induction of MCPIP1 in human ﬁbroblasts embedded in the stress-released 3-D collagen matrix, which occurred
through activation of mitogen-activated protein kinases, phosphoinositide 3-kinase, and NF-κB. Furthermore,
MCPIP1 induction was associated with inhibition of ﬁbroblast migration out of the nested collagen matrix.
MCPIP1 induction or ectopic expression also upregulated p53. RNA interference of p53 prevented the inhibition
of migration produced by induction or ectopic expression of MCPIP1. Our ﬁndings suggest a new role for
MCPIP1 as a molecular switch that regulates ﬁbroblast migration in the nested collagen matrix model.
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INTRODUCTION
Recently, we observed (Chao et al., 2014) that foreskin
ﬁbroblasts preconditioned in a rigidly anchored collagen
matrix migrated out of that matrix when it was re-embedded
(“nested” Grinnell et al., 2006) in cell-free, anchored
collagen, whereas ﬁbroblasts preconditioned in a stress-
released matrix had relatively poor motility under the same
conditions (5% serum). This observation provided us with an
opportunity to study mechanoregulation of ﬁbroblast motility
in the ﬁbroblast-populated three-dimensional (3-D) collagen
matrix (FPCM) model (Grinnell, 1994). A relevant signaling
molecule was MCPIP1 (MCP-1-induced protein 1, also
known as ZC3H12A), a 66 kDa protein identiﬁed in human
peripheral blood monocytes and cardiomyocytes stimulated
with MCP-1 (monocyte chemotactic protein 1; Zhou et al.,
2006; Liu et al., 2015). The known functions of MCPIP1
include the following: downregulation of inﬂammation
through induction of apoptosis genes (Zhou et al., 2006;
Skalniak et al., 2013); induction of angiogenesis in
endothelial cells (human umbilical vein endothelial cells;
Niu et al., 2008); inhibition of Toll-like receptor signaling and
macrophage activation (Huang et al., 2012); upregulation of
adipogenesis independent of peroxisome proliferator–
activated receptor-γ (Younce et al., 2009); RNAse activity
against viral DNA (Suzuki et al., 2011; Lin et al., 2013);
inhibition of c-Jun N-terminal kinase (JNK) and NF-κB (Liang
et al., 2008; Liu et al., 2013); and protection against
lipopolysaccharide-induced shock (Huang et al., 2013).
MCPIP1-deﬁcient mice developed a severe inﬂammatory
syndrome with T-cell activation, increased cytokine produc-
tion, and a 50% 8-week mortality (Miao et al., 2013).
MCPIP1 also was noted to promote migration in human
umbilical vein endothelial cells (Niu et al., 2008), and MCP-1
knock-out mice demonstrated delayed wound re-
epithelialization and angiogenesis (Low et al., 2001). Thus, it
seemed logical to test whether MCPIP1 participated in
mechanoregulation of ﬁbroblast healing functions, such as
proliferation, contraction, and migration. Herein we report data
demonstrating that MCPIP1 induction after stress release of the
FPCM inhibits ﬁbroblast migration, working through a signaling
pathway involving the mitogen-activated protein kinases
(MAPK), NF-κB, and p53. This brake on ﬁbroblast migration
appears to be a new function for MCPIP1 and implicates this
protein as a participant in the wound healing process.
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RESULTS
Mechanoregulation of migration in the restrained nested matrix;
upregulation of MCPIP1 in the stress-released FPCM
Fibroblast migration was assayed using serum-treated
attached or stress-released collagen matrices populated with
green ﬂuorescent protein (GFP)-expressing human foreskin
ﬁbroblasts (HFFs) (Chao et al., 2014) in the restrained nested
matrix (Supplementary Figure S1A online; Miron-Mendoza
et al., 2010). Fibroblast migration out of the nested stress-
released matrix was decreased relative to the nested stressed
(attached) matrix (Figure 1a and b and Supplementary Figure
S4F online). Immunoblotting demonstrated that the MCPIP1
protein was upregulated after matrix release (Figure 1c and d).
The MCPIP1 signal reached a maximum at ~ 1 hour and
remained elevated for several days. Immunocytochemistry of
MCPIP1 in attached versus released matrices also demon-
strated induction of this protein in the released state
(Figure 1e). The speciﬁcity of the MCPIP1 ﬂuorescence in
the released matrix was particularly impressive while focusing
up and down through the 3-D microscopy specimen.
Effect of MCPIP1 RNAi on the mechanoregulation of FPCM
contraction, matrix cell number, and ﬁbroblast migration
In order to determine whether MCPIP1 induction associated
with FPCM stress release was biologically relevant, the effect of
MCPIP1 knockdown on FPCM contraction, matrix cell number,
and ﬁbroblast migration was determined in attached versus
released matrices. The efﬁciency of MCPIP1 RNA interference
(RNAi) in the attached versus released FPCM (72 hours after
transfection, 24 hours after release) was near complete by
immunoblotting (Figure 2a). RNAi of MCPIP1 had minimal
effect on contraction in the ﬂoating collagen matrix assay
(“dermal equivalent” (Grinnell and Petroll, 2010)); see Figure 2b
and c. RNAi of MCPIP1 did not affect the decrease in matrix cell
number (Figure 2d) known to occur after matrix stress release
(Carlson and Longaker, 2004). Using attached or stress-released
matrices populated with GFP-expressing HFFs nested into
restrained cell-free collagen, it was observed that MCPIP1
knockdown disinhibited migration out of the released, nested
matrix (Figure 2e and f)––i.e., the decrease in ﬁbroblast migration
(the inhibition) precipitated by release of the nested matrix was
prevented (disinhibited) if MCPIP1 expression was blocked.
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Figure 1. Effect of ﬁbroblast-populated three-dimensional (3-D) collagen matrix (FPCM) release on ﬁbroblast migration and expression of monocyte
chemotactic protein–induced protein 1 (MCPIP1). (a) Migration of green ﬂuorescent protein (GFP)-expressing ﬁbroblasts out of nested matrices was decreased
24 hours after matrix release. Fibroblast migration shown at the interface between the nested matrix and the restrained cell-free matrix. Left scale bar=200 μm,
right scale bar= 80 μm. (b) Plot of migration (three separate experiments from panel a). (c) MCPIP1 induction after FPCM release. Whole-cell lysates from
attached or released matrices immunoblotted for MCPIP1 and β-actin. (d) MCPIP1 densitometry (four separate experiments from panel c). (e) MCPIP1
immunocytochemistry in the attached versus released FPCM. Blue=DAPI; green=MCPIP1. Scale bar= 20 μm. Data are mean± SEM.; *Po0.05 versus attached
(unpaired t-test).
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Figure 2. Effect of monocyte chemotactic protein–induced protein 1 (MCPIP1) RNAi or ectopic expression on matrix contraction, matrix cell number, and
ﬁbroblast migration. (a) Immunoblots of lysates from ﬁbroblast-populated three-dimensional (3-D) collagen matrix (FPCMs) expressing siRNA (MCPIP1 versus
nonsense). (b and c) Effect of MCPIP1 RNAi on FPCM contraction (well diameter=19mm); plot= three experiments. (d) Effect of MCPIP1 RNAi on FPCM cell
number, 1-day post release. (e and f) Effect of MCPIP1 RNAi on migration out of the released, nested FPCM (scale bar=80 μm); plot= three experiments.
(g) Immunoblots of lysates from FPCMs expressing MCPIP1-Flag versus Flag. (h and i) Effect of MCPIP1-Flag expression on FPCM contraction; plot= three
experiments. (j) Effect of MCPIP1-Flag expression on FPCM cell number, 1-day post release. (k and l) Effect of MCPIP1-Flag expression on migration out of the
attached, nested FPCM (scale bar= 80 μm); plot= three experiments. *Po0.05, unpaired t-test.
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Effect of MCPIP1 ectopic expression on the mechanoregulation
of FPCM contraction, matrix cell number, and ﬁbroblast
migration
In order to corroborate the ﬁndings in Figure 2, an analogous
set of experiments was performed using plasmid-expressed
Flag-tagged MCPIP1 (Figure 2g and l). Conﬁrmation of
MCPIP1-Flag expression after plasmid transfection in the
FPCM is shown in Figure 2g and Supplementary Figure S1B
online. Addition of the MAT-Tag-Flag sequence (see Materials
and Methods section) added 15 amino acids to the 599 amino
acid sequence of MCPIP1, but no shift was seen on the
immunoblots of MCPIP1 versus MCPIP1-Flag. Subsequent
ectopic expression of MCPIP1-Flag had no effect on contrac-
tion in the ﬂoating collagen matrix assay (Figure 2h and i).
Expression of MCPIP1-Flag also did not affect the decrease in
matrix cell number, which occurred after matrix stress release
(Figure 2j). In experiments analogous to those in Figure 2e
and f, expression of MCPIP1-Flag inhibited GFP-HFF migra-
tion out of the attached matrix nested into restrained, cell-free
collagen (Figure 2k and l). Ectopic expression of MCPIP1-Flag
in monolayer ﬁbroblasts actually increased migration in a
scratch assay (Supplementary Figure 5A and B online)––i.e.,
the opposite effect to that observed in the 3-D culture model.
Effect of FPCM release on phosphorylation of MAPK and Akt
Previous reports have indicated that activation of MAPK and
the phosphoinositide 3-kinase (PI3K)/Akt pathway both
stimulate ﬁbroblast migration (Li et al., 2004; Clement et al.,
2013). In order to see whether there was a link between these
kinase pathways and MCPIP1-associated inhibition of cellular
migration, phosphorylation of these kinases in the attached
versus released FPCM was evaluated ﬁrst (Figure 3). Within
5minutes of matrix stress release, there was increased
phosphorylation of Erk, which tapered off by 6 hours (Figure
3a and c). Within 5–10minutes of release, p38 demonstrated
increased phosphorylation, reaching a peak around 30–60
minutes and then tapering off (Figure 3a and b). JNK also
demonstrated a burst of activation from 5 to 30minutes after
release (Figure 3d and e). The data of Figure 3 were consistent
with previous work of other investigators, who demonstrated
Erk and p38 activation after stress release of the FPCM under
similar but not identical conditions (Lee et al., 2000).
Akt also demonstrated a burst of activity 1 hour after
release, with tapering thereafter (Figure 3d and f). Of note,
previously published reports demonstrated that Akt was
dephosphorylated during a longer time course (46 hours) of
FPCM stress release (Tian et al., 2002; Carlson et al., 2004;
Xia et al., 2004). A long time course of Akt activity after matrix
release was repeated for corroboration purposes in Supple-
mentary Figure S2A and B online, which again demonstrated
rapid and transient Akt phosphorylation, followed by gradual
dephosphorlyation evident at 6–12 hours (consistent with
previously published data).
Effect of pharmacological inhibition of MAPK or Akt on MCPIP1
induction and ﬁbroblast migration after FPCM release
Pharmacological inhibition of the above kinases was used to
determine whether the pathways of interest (JNK, ERK, p38,
and PI3K/Akt) regulated (i) the expression of MCPIP1 and (ii)
ﬁbroblast migration out of the nested matrix (Figure 3g and l).
Justiﬁcation for the 30-minute point was the relatively large
increase in MCPIP1 expression in the released matrix present
at this time; the 24-hour time point was chosen because both
MCPIP1 upregulation and migration inhibition were evident
24 hours after release (Figure 1). Treatment of FPCMs with
commercially available small molecules U0126 (MEK inhi-
bitor), SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), or
LY294002 (PI3K inhibitor) at the manufacturer-recommended
dose decreased the stress-release-induced phosphorylation of
the respective target kinase (see Supplementary Figure S2C
and F online).
Inhibitor pre-treatment for 2 hours prior to FPCM stress
release diminished the induction of MCPIP1 at both 30
minutes and 24 hours after stress release (Figure 3g and j). At
the 30-minute time point, the MCPIP1 signal still appeared
to be increased in the stress-released matrix in the presence
of each kinase inhibitor, but this reached signiﬁcance only
with the p38 inhibitor (SB203580). At the 24-hour time point,
induction of MCPIP1 expression after stress release was still
blunted by each kinase inhibitor, but effects were less
pronounced compared with the 30-minute time point
(Figure 3j).
Analysis of variance and unpaired t-testing performed
on the MCPIP1/actin expression ratios for the attached
matrix in Figure 3j (i.e., attached vehicle versus attached
SP600125 versus attached U0126 versus attached
SB203580 versus attached LY294002) revealed that the
attached LY294002 ratio (indicated with an asterisk over
that bar) was different from the attached vehicle ratio.
Thus, although kinase inhibition may have decreased
MCPIP1 expression in the attached FPCM, our assay detected
this only for the PI3 K inhibitor. This observation might
decrease the relevance of the decrease in MCPIP1 induction
observed in the LY294002-treated released matrix; the
absolute effect of the PI3K inhibitor in the released matrix,
however, was still large compared with the effect in the
attached matrix.
The effect of pharmacologic inhibition of kinase activity on
ﬁbroblast migration from stress-released matrices nested into
restrained cell-free matrices then was evaluated (Figure 3k
and l). Pre-treatment of the FPCM for 2 hours prior to stress
release with the MEK, p38, or JNK inhibitor enhanced
ﬁbroblast migration out of the nested released matrix (i.e.,
resulted in disinhibition of ﬁbroblast migration). Pre-treatment
of matrices with the PI3K inhibitor LY294002, however, did
not have an effect––that is, ﬁbroblast migration out of the
nested released matrix was similar to vehicle treatment,
meaning barely detectable. There was no signiﬁcant effect of
any of these inhibitors on ﬁbroblast migration out of the
nested attached matrix (Supplementary Figure S3A and B
online). The data of Figure 3 suggested that MAPK activation
was upstream of MCPIP1 induction in a putative pathway
that inhibited ﬁbroblast migration after stress release of
the FPCM.
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Involvement of NF-κB in the expression of MCPIP1 and
inhibition of ﬁbroblast migration after FPCM release
NF-κB activation has been documented in the contractile
FPCM (Xu and Clark, 1997; Xu et al., 1998; Carlson et al.,
2013), and NF-κB signaling has been implicated in the
induction of both MCP-1 and MCPIP1 in endothelial cells (Qi
et al., 2010; Yao et al., 2010). In addition, NF-κB activation
can occur secondary to MAPK activation (Troppmair et al.,
1998; Dhawan and Richmond, 2002; Dong et al., 2012).
Hence, it was hypothesized that MCPIP1 induction in the
stress-released FPCM occurred as a consequence of MAPK–
mediated NF-κB activation. During the 5–30 -minute interval
after matrix release, there was an increase in the level of the
phosphorylated p65 (p-p65) subunit of NF-κB in the nuclear
fraction of the HFFs (Figure 4a and b), with a concomitant loss
of this subunit in the cytoplasm (Supplementary Figure S4A
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Figure 4. NF-κB signaling, monocyte chemotactic protein–induced protein 1 (MCPIP1) induction, and inhibition of migration in the ﬁbroblast-populated
three-dimensional (3-D) collagen matrix (FPCM). (a and b) NF-κB p65 phosphorylation after FPCM release (nuclear fraction immunoblots); n= 4 experiments for
densitometry. (c and d) Effect of kinase inhibitors on p-p65 in attached versus 20-minute-released FPCMs; n=4 experiments for densitometry. (e) NF-κB p65
binding sequence, MCPIP1 promoter region. (f) Chromatin immunoprecipitation of p65 binding to the MCPIP1 promoter, 20minutes after FPCM release. (g and h)
Effect of NF-κB activation inhibitor (SC-514) on MCPIP1 induction after FPCM release (24-hour time point; whole-cell immunoblots); n=4 experiments for
densitometry. (i) Effect of SC-514 resulted on migration out of the nested released FPCM (immunoﬂuorescent images in Supplementary Figure S1C and D online);
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Figure 3. Kinase activity, inhibition, monocyte chemotactic protein–induced protein 1 (MCPIP1) expression, and migration in the ﬁbroblast-populated three-
dimensional (3-D) collagen matrix (FPCM). (a–f) p38, Erk1/2, c-Jun N-terminal kinase (JNK), and Akt phosphorylation after FPCM release (immunoblots of whole
lysates), with densitometry of n=4 experiments. (g–j) Effect of kinase inhibitors (JNK= SP600125, MEK=U0126, p38= SB203580, PI3K= LY294002) on FPCM
MCPIP1, 30 minutes and 24 hours post release (whole-lysate immunoblots), with densitometry (n=4 experiments each). *Po0.05 versus vehicle-attached
(unpaired t-test); #Po0.05 versus vehicle-released (unpaired t-test). (k and l) Effect of kinase inhibitors on migration out of the released, nested matrix (upper scale
bar=200 μm, lower scale bar= 80 μm); plot represents n= 3 experiments/condition. *Po0.05, unpaired t-test.
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online), consistent with pilot data (Carlson et al., 2013). This
increase in p-p65 after matrix release appeared to be
abrogated if the matrices were pre-treated with pharmacolo-
gic inhibitors of Erk, p38, or JNK; pre-treatment with the PI3K
inhibitor had less effect (Figure 4c and d). These results
suggested that MAPK activation after FPCM release resulted in
NF-κB activation.
The MCP-1 promoter has an NF-κB binding site (Yao et al.,
2010); a chromatin immunoprecipitation assay was utilized to
determine whether a similar site was present on the MCPIP1
promoter (Figure 4e). Chromatin was cross-linked to protein
in attached versus 20-minute stress-released FPCMs, and
sonicated extracts were processed with a chromatin immuno-
precipitation kit (EMD Millipore, Billerica, MA). Subsequent
agarose gel electrophoresis of the ampliﬁed, immunoprecipi-
tated DNA revealed much greater NF-κB binding in extracts
from the released matrix compared with the attached
(Figure 4f). This was consistent with NF-κB binding to the
MCPIP1 promoter in extracts from the stress-released FPCM.
In order to determine whether NF-κB activation after FPCM
release regulated MCPIP1 induction, matrices were pre-treated
with pharmacologic inhibitors of NF-κB activation (Figure 4g
and i, Supplementary Figure S1C and D, and S4D and F online),
including TPCK (N-p-tosyl-L-phenylalanine chloromethyl
ketone) and SC-514 (4-Amino-[2,3"]bithiophenyl-5-carboxylic
acid amide). TPCK, a serine protease inhibitor, will block NF-κB
activation by preventing the proteolysis of IκB-α SC-514, an
ATP-competitive inhibitor selective for IκB kinase-2 (IKK-2), will
block NF-κB activation by preventing phosphorylation of IκB-α
(Henkel et al., 1993; Kishore et al., 2003; Karin et al., 2004; Ha
et al., 2009). Compared with vehicle-treated matrices, MCPIP1
induction after release in matrices pre-treated with SC-514 or
TPCK or was not present at 24 hours (Figure 4g and h and
Supplementary Figure S4D and E online, respectively). Further-
more, FPCM pre-treatment with either SC-514 or TPCK
disinhibited HFF migration in the released matrix that was nested
into a restrained, cell-free matrix (Figure 4i,Supplementary Figure
S1C and D, and S4F online). In other words, pharmacologic
inhibition of NF-κB allowed ﬁbroblasts to migrate out of the
collagen matrix under conditions in which they normally would
not. The results thus far suggested that inhibition of ﬁbroblast
migration associated with FPCM release involved a pathway
with sequential upregulation of MAPK, NF-κB, and MCPIP1.
Interaction of MCPIP1 with p53 after release of the FPCM
It has been shown that p53 is upregulated after release of
the FPCM (Carlson et al., 2004, 2009, 2013). In order to
determine whether there was co-localization of MCPIP1
and p53 after release of the FPCM, double-immunocyto-
chemistry for these two antigens was performed (Figure 5a
and Supplementary Figure S3E online). The orange-yellow
coloring in the merged images indicated that there was some
co-localization of MCPIP1 and p53 in the 1 day-released
matrix. Immunoprecipitation of either MCPIP1 or p53
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followed by immunoblotting for the opposite antigen demon-
strated an association of MCPIP1 and p53 in whole-cell
lysates from the released (but not attached) FPCM (Figure 5b
and c). Control immunoprecipitation experiments that used
RNAi to knockdown either MCPIP1 or p53 prior to pull-down
conﬁrmed the speciﬁcity of the MCPIP1-p53 association
(Supplementary Figure S3C and D online. The results from
Figure 5a and c suggested that there was a physical inter-
action between MCPIP1 and p53 after FPCM stress release.
In order to determine whether one of these proteins
regulated the concentration of the other, RNAi of MCPIP1
or p53 was performed, and protein levels were determined
with immunoblotting (Figure 5d and f). Fibroblasts transfected
with siRNA against MCPIP1 did not have p53 upregulation
24 hours after matrix release (Figure 5f), even though the
knockdown of MCPIP1 did not appear complete (Figure 5e).
Treatment with siRNA against p53 prevented most of the post-
release increase in p53 (Figure 5d and f). Dissimilar to the
situation with MCPIP1 RNAi, however, partial knockdown of
p53 did not affect the induction of MCPIP1 in the released
matrix (Figure 5d and e). These data suggested that MCPIP1
regulated p53 induction after FPCM release––i.e., MCPIP1
was upstream of p53 in a putative pathway.
Further exploration of an MCPIP1-p53 relationship was
carried out using ectopic expression of MCPIP1-Flag com-
bined with p53 RNAi (Figure 6). Expression of MCPIP1-Flag
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upregulated p53 in the attached FPCM, with no signiﬁcant
effect in the released matrix (Figure 6a and c); as expected,
MCPIP1-Flag inhibited cell migration out of the nested
attached FPCM (Figure 6d and e). Consistent with Figure 5,
RNAi of p53 did not affect induction of MCPIP1 associated
with matrix release (Figure 6a and b) but did result in
disinhibition of cell migration that occurred in the nested
released FPCM (Figure 6d and e). Expression of MCPIP1-Flag
could not overcome the effect of p53 RNAi on cell migration
(Figure 6d and e). In other words, MCPIP1 could inhibit
the ability of ﬁbroblasts to migrate out of the attached matrix
that was nested into a restrained, cell-free matrix if p53 was
not inhibited. If p53 was knocked down, however, then
the ﬁbroblasts could migrate out of either an attached or a
released matrix, regardless of the state of MCPIP1.
MCPIP1 associated with USP10 (ubiquitin speciﬁc pepti-
dase 10) after genotoxic stress, enhancing the latter’s
deubiquitinase activity, thereby producing deubiquitination
of NEMO (IKK-γ), which resulted in inhibition of NF-κB
activation (Niu et al., 2013). Genotoxic stress also produced a
TANK-MCPIP1-USP10 complex that effected/enhanced deu-
biquitination of both TRAF6 (E3 Ubiquitin Protein Ligase) and
NEMO, which in turn inhibited NF-κB activation (Wang et al.,
2015). Therefore, in the setting of genotoxic stress, MCPIP1
appears to function as a facilitator of USP10 deubiquitinase,
thereby acting as a “brake” (negative feedback mechanism)
on NF-κB activation. In order to determine whether MCPIP1
facilitation of deubiquitination was relevant for MCPIP1-
induced upregulation of the p53 protein, we performed FPCM
experiments with ﬁbroblasts transfected with MCPIP1(ΔZF),
an MCPIP1 mutant that does not promote deubiquitination
(Liang et al., 2010). Our data suggested that MCPIP1-facili-
tated deubiquitination is important for induction of p53
by MCPIP1 (Supplementary Figure 4B and C online),
which suggested that the increase in the p53 protein after
FPCM stress release was mediated at least in part by a
decrease in p53 ubiquitination. Whether MCPIP1 affects the
ubiquitination status of p53 through USP10 will need further
investigation.
The data of Figure 6 were consistent with a pathway in
which MCPIP1, acting upstream and through p53, effected
inhibition of cell migration out of the nested released FPCM.
Stress release of the FPCM also has been shown both to
increase apoptosis and inhibit the cell cycle in the resident
ﬁbroblasts (Fluck et al., 1998; Grinnell et al., 1999; Tian et al.,
2002; Carlson and Longaker, 2004; Hadjipanayi et al., 2009;
Carlson et al., 2013), which likely is an effect of p53
upregulation. Although cell survival and proliferation were
not the focus of this study, we did demonstrate that the
Bax protein increased after FPCM stress release and that this
induction was abrogated by p53 knockdown (Supplementary
Figure 5C online). This ﬁnding would be consistent with a
p53-modulated increase in apoptosis associated with FPCM
stress release.
DISCUSSION
The data suggested the existence of an MCPIP1-centric
network that regulated ﬁbroblast migration in the nested
FPCM model (Figure 6f and g). In this putative network,
MCPIP1 in the nested attached FPCM was undetectable,
allowing ﬁbroblasts to migrate out of the FPCM and into the
acellular neomatrix. If the matrix was released, however,
phosphorylation of MAPK (Erk, p38, and JNK) ensued and
produced NF-κB activation. The p65 subunit of NF-κB then
bound to the promoter region of the MCPIP1 gene, followed
by increased MCPIP1 expression. This induction of MCPIP1
upregulated p53, possibly through binding events between
MCPIP1 and p53 (and perhaps some unspeciﬁed scaffolding
proteins). Upregulation of p53 produced, through unidentiﬁed
additional steps, inhibition of ﬁbroblast migration out of the
nested released matrix.
Although we have implied that MCPIP1 induction after
FPCM release was secondary to increased transcription and
translation, we have not ruled out other protein turnover
mechanisms, such as transcript stability or protein degrada-
tion. Our assumption of increased MCPIP1 transcription was
based on two observations: (i) p65 NF-κB bound to the
MCPIP1 promoter after FPCM release; and (ii) inhibition of
NF-κB activation abrogated both the induction of MCPIP1
and the inhibition of migration that occurred after matrix
release (Figure 6).
It is conceivable that other signaling events (e.g., involving
the Rho GTPases (Raftopoulou and Hall, 2004)) may have
contributed to the inhibition of migration associated with
FPCM stress release. Nevertheless, various “molecular
switches” have been described in which a change in the
protein level and/or activity produced a large downstream
event (Milburn et al., 1990; Murphy et al., 2004; Drees et al.,
2005); hence, it is not inconceivable that increased MCPIP1
protein contributed to the inhibition of ﬁbroblast migration.
The effect of MAPK inhibition on MCPIP1 induction in
Figure 6 was partial, suggesting that the MAPK inhibitors may
have had produced other downstream effects (e.g., on myosin
light chain kinase (Huang et al., 2004)) that resulted in
disinhibition of migration after matrix stress release.
Previous reports have suggested that activation of onco-
genic Ras, MAPK, and PI3K all may work to enhance
ﬁbroblast migration (Li et al., 2004; Menezes et al., 2008;
Clement et al., 2013), in apparent contradiction to our report.
These earlier reports all used one or more of the following
conditions: (i) transformed cell lines with forced/sustained
expression of various signaling proteins; (ii) monolayer culture
conditions; and (iii) variable amounts of soluble growth
factors. In contrast, our experimental system (i) did not utilize
forced expression to make primary observations (Figures 1
and 4), (ii) did utilize a 3-D culture system, and (iii)
maintained a constant culture medium. These differences in
experimental design might explain the discrepancy between
the previous studies and our data. For example, we observed
transient MAPK activation, the effect of which likely is
different from activation secondary to forced expression
(Marshall, 1995; Sabbagh et al., 2001).
Our intent herein was to study ﬁbroblast migration in a
tractable 3-D model that has morphologic and physiologic
similarities to dermal wounds (Carlson and Longaker, 2004);
clearly, these results may not perfectly translate to in vivo
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processes. It is interesting to note that forced expression of
MCPIP1 in a monolayer assay of migration actually appeared
to promote ﬁbroblast motility––i.e., the opposite effect to what
was observed in the 3-D collagen matrix. This discordance of
experimental results from monolayer versus 3-D culture
systems suggests that it may be better to utilize 3-D culture
systems when studying cells whose natural environment is
three-dimensional not planar (Cukierman et al., 2001).
The FPCM model has been in continual use since the 1970s
to study various phenomena related to wound healing, such
as cellular migration, cell-mediated matrix contraction,
synthesis and secretion of matrix proteins, cell death,
and cellular proliferation. Derivatives of the FPCM model
also have been used to study tissue engineering (Carlson and
Longaker, 2004; Grinnell and Petroll, 2010; Harunaga and
Yamada, 2011; Kim et al., 2011). Continued progress in
wound healing science likely will beneﬁt from the use of (i)
culture systems such as the FPCM and (ii) in vivo models.
MATERIALS AND METHODS
Cell culture
The use of primary dermal ﬁbroblasts derived from discarded human
neonatal circumcision specimens was approved by the Research and
Development Committee of the Omaha VA Medical Center and by
the Institutional Review Board of the University of Nebraska Medical
Center. Fibroblasts were cultured from explants of human neonatal
foreskins, as previously described (Carlson et al., 2009). The collagen
matrix model was utilized, as previously described (Grinnell et al.,
1999; Carlson et al., 2009, 2013). Lentiviral-transduced HFFs with
stable expression of GFP was described in a separate report (Chao
et al., 2014).
Nested matrix model and cell migration
The nested collagen matrix model was utilized as previously described
(Grinnell et al., 2006; Miron-Mendoza et al., 2010; Chao et al., 2014;
Liu et al., 2015) with some modiﬁcations; refer to Supplementary Figure
S1A and protocol in the Supplementary Information online. For the
nested attached matrix, a standard FPCM was incubated in the attached
state for 72 hours with 5% fetal bovine serum in DMEM; the FPCM then
was removed from the culture well and placed onto a 60-μl aliquot of
fresh acellular collagen matrix solution (neomatrix solution) that was
centered inside a 12mm-diameter score on the bottom of a new culture
well. A 140-μl aliquot of neomatrix solution then was used to cover the
newly transferred FPCM. The neomatrix was allowed to polymerize for
1 hour at 37 °C and 5% CO2, and then 2ml of DMEM with 5% fetal
bovine serum was added to the well. The same procedure was followed
for the nested released matrix, except that the initial incubation of the
FPCMwas 48 hours in the attached stated, followed by detachment, and
then 24-hour incubation in the released state (see Supplementary Figure
S1A online). Cell migration out of the nested FPCM and into the acellular
neomatrix was quantiﬁed 24 hours after nesting with ﬂuorescent
microscopy, as described in the Supplementary Information online. Cell
number per matrix was determined using a Scepter Cell Counter (EMD
Millipore, Billerica, MA), as previously described (Chao et al., 2014).
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